Intravenous Immunoglobulin Therapy in Children Vasculitis: A Systematic Review

Introduction: IVIG therapy represents a valuable therapeutic option in the management of pediatric vasculitis, offering immunomodulatory effects, and favorable safety outcomes. By targeting multiple pathogenic pathways implicated in vasculitic disease processes, IVIG helps alleviate inflammation, reduce disease activity, and improve clinical outcomes in affected children.Material and methods: Two independent reviewers screened the titles and abstracts of retrieved articles to assess eligibility based on the predefined inclusion and exclusion criteria. Full-text articles of potentially relevant studies were then obtained and assessed for final inclusion. Data extraction was performed using a standardized form, capturing relevant information such as study characteristics (author, publication year, study design), patient demographics, vasculitis subtype, IVIG regimen (dosage, duration), primary and secondary outcomes, adverse events, and follow-up duration.Results: Across the included studies, IVIG therapy demonstrated favorable treatment outcomes in pediatric patients with various forms of vasculitis. The most common vasculitis types investigated were Kawasaki disease, Henoch-Schönlein purpura, Takayasu arteritis, and polyarteritis nodosa.Conclusion: IVIG therapy represents a valuable treatment modality for children with vasculitis, offering immunomodulatory effects that can attenuate inflammation, preserve organ function, and improve clinical outcomes. The mechanisms of action of IVIG involve modulation of the immune response, inhibition of autoantibody production, and restoration of immune homeostasis.

Keywords:

IVIG therapy , vasculitis , children , Systematic review